CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cordsWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug286 BCG vaccine (Freeze-dried) Wiki 1.00

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.10
D012128 Respiratory Distress Syndrome, Adult NIH 0.09

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Study of Mesenchymal Stem Cells as a Treatment in Patients With Acute Respiratory Distress Syndrome Caused by COVID-19

This is a pilot phase, open label, non-randomized study for the treatment of ARDS in patients infected with COVID-19. Subjects will be enrolled and treated with one dose of mesenchymal stem cells and follow-up will occur 90 days post-treatment.

NCT04456361 ARDS, Human Covid-19 Biological: Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords
MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury

Primary Outcomes

Description: Number of patients with changes in percentage of resting Oxygen saturation (%O2)

Measure: Oxygen saturation

Time: Baseline, and at days 2, 4 and 14 post-treatment

Secondary Outcomes

Description: Changes in mmHg of Arterial partial pressure of oxygen / Fraction of inspiration O2 (PaO2/FiO2) in all participants

Measure: Oxygen pressure in inspiration

Time: Baseline, and at days 2, 4 and 14 post-treatment

Description: Changes in percentage of participants with reduction in bilateral ground-glass opacities

Measure: ground-glass opacity

Time: Baseline, and at day 14 post-treatment

Description: Changes in percentage of participants with reduction of pneumonia bilateral infiltration

Measure: Pneumonia infiltration

Time: Baseline, and at day 14 post-treatment

Description: Number of participants with a reduction in Lactate dehydrogenase (mg/dL)

Measure: Lactate dehydrogenase

Time: Baseline, and at days 4 and 14 post-treatment

Description: Number of participants with a reduction in C-reactive protein (mg/dL)

Measure: C-reactive protein

Time: Baseline, and at days 4 and 14 post-treatment

Description: Number of participants with a reduction in D-dimer (mg/dL)

Measure: D-dimer

Time: Baseline, and at days 4 and 14 post-treatment

Description: Number of participants with a reduction in Ferritine (mg/dL)

Measure: Ferritine

Time: Baseline, and at days 4 and 14 post-treatment

No related HPO nodes (Using clinical trials)